A humanized anti-EphA3 antibody (ifabotuzumab) has shown specific tumor targeting in early phase clinical studies for hematologic malignancies24 (NCT01211691) and GBM (NCT03374943) reinforcing its potential as a therapeutic target. The gene discussed is EPHA3; the disease is neoplasm.